Advertisements

Trimzole DS

Quick links to important sections

Trimzole DS

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Trimzole DS

Property Description
Active ingredients Sulfamethoxazole, Trimethoprim
Form Tablet (Double Strength - DS), Suspension, Solution for Infusion
Pharmacological Class Antibiotic, Antimicrobial
General Purpose Fighting a wide range of bacterial infections
Origin Synthetic

What Type of Medicine is Trimzole DS (Co-trimoxazole)?

Trimzole DS is a brand designation for the synthetic fixed-dose combination drug known generically as Co-trimoxazole. It is classified as an antibiotic and potent antimicrobial agent, typically supplied for the oral route as a tablet or liquid suspension. The "DS" designation is a key distinguishing feature signifying Double Strength, which is a higher concentration of the active ingredients compared to the standard tablet formulation. This class of medicine is clinically recognized for its broad utility in combating various infectious disease scenarios.

Composition: What Active Ingredients are in Trimzole DS?

The product is composed of two distinct active ingredients: Sulfamethoxazole (SMX), which belongs to the sulfonamide antibiotic class, and Trimethoprim (TMP), which is categorized as a dihydrofolate reductase inhibitor. This specific combination is listed as an Essential Medicine, underscoring its established importance in public health. The formulation is intentionally a combination product, where the two compounds are included to work together, delivering an enhanced synergistic effect that is crucial to the medicine's efficacy, often referenced by the abbreviation TMP-SMX.

General Purpose of this Antibiotic Combination

The general therapeutic purpose of this drug is to combat a wide spectrum of common bacterial infections, such as those affecting the urinary tract. This combined approach is highly effective because it employs a dual mechanism that interrupts the bacteria's ability to produce folic acid, a necessary compound for their survival and cell division. By achieving this simultaneous and sequential inhibition of bacterial folic acid synthesis, the drug exerts a powerful bactericidal (germ-killing) effect, preventing the infection from multiplying or sustaining itself.

Regulatory References

  1. Co-trimoxazole
  2. Sulfamethoxazole/Trimethoprim Drug Information
  3. Essential Medicine List
Advertisements

What side effects are possible with Trimzole DS?

Possible Side Effects and Safety Information

The safety profile for Trimzole DS (Co-trimoxazole) is structured by government regulatory agencies based on System-Organ Classes (SOCs) and frequency classifications, defining its documented risks.


Frequency-Classified Adverse Reactions

Adverse reactions are categorized by how often they are officially documented:

  • Very Common (ge 1/10): Hyperkalaemia (elevated blood potassium levels), which falls under Metabolism and Nutrition Disorders.
  • Common (ge 1/100 to <1/10): Fungal overgrowth (Candidiasis), Headache, Nausea, Diarrhea, and Rash.
  • Very Rare (<1/10,000): Includes severe conditions such as Severe Cutaneous Reactions (e.g., SJS/TEN), Hepatic Necrosis, Agranulocytosis (a severe blood disorder), and Aseptic Meningitis.

Serious Adverse Reactions and Safety Constraints

Regulatory documents emphasize the risk of Severe Cutaneous Reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are potentially fatal. Other serious events include severe Blood Dyscrasias (e.g., Aplastic Anemia) and Fulminant Hepatic Necrosis.

Safety notes also define specific constraints:

  • Population-Specific: The medicine is contraindicated in infants less than two months of age. Older adults are noted to have an increased risk of serious adverse effects. Special considerations apply to patients with severe renal or hepatic impairment.
  • Time-Related Patterns: The risk for severe skin reactions is explicitly stated to be highest within the first weeks of treatment. Furthermore, Clostridioides difficile-associated diarrhea may occur up to two months or more after stopping therapy.

The regulatory safety structure defines the drug's risk profile, focusing on officially listed reactions and restrictions without offering clinical instruction or advice.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medication, which contains sulfamethoxazole and trimethoprim, presents risks that require immediate medical attention. The official documentation defines two primary risks: acute overdose and chronic overexposure.

Acute Overdose Presentations

Symptoms following an acute overdose may affect multiple body systems and include:

  • Gastrointestinal/Systemic: Loss of appetite, vomiting, fever.
  • Central Nervous System (CNS): Confusion, dizziness, or loss of consciousness.
  • Hepatic/Renal: Yellowing of the skin or eyes (jaundice), or the presence of blood in the urine.

Chronic Overexposure Risk

Chronic overdosage is associated with a risk of bone marrow depression, which can manifest as low blood cell counts, specifically thrombocytopenia (low platelets) or leukopenia (low white blood cells). This is related to the trimethoprim component's effect on the body's folate metabolism.

When to Seek Immediate Medical Help

Seek emergency medical attention or call the Poison Control Help line immediately if an overdose is suspected. Urgent medical services (such as 911) must be called immediately if the affected individual has:

  • Collapsed or had a seizure.
  • Trouble breathing.
  • Cannot be awakened.
Advertisements

Therapeutic Uses of Trimzole DS

What Trimzole DS Treats: Main Uses and Benefits

Trimzole DS is commonly used for managing bacterial infections across several therapeutic domains and plays a role in managing symptoms during acute episodes of illness. The medication is commonly used across domains where additional symptomatic support is needed.


Easing Urogenital and Systemic Infection Symptoms

This medication is commonly used to treat uncomplicated urinary tract infections (UTIs), which present with symptoms related to physical discomfort like painful urination (dysuria), frequency, and urgency. It is applied in situations involving recurrent or acute manifestations. The management of the infectious process contributes to easing the overall symptom load and assists with maintaining functional stability and comfort during symptomatic periods.


Supporting Respiratory and Opportunistic Infection Management

Trimzole DS helps address symptom clusters in the airways, such as cough, fever, and excess sputum that may be linked to a bacterial acute exacerbation of chronic bronchitis (AECB). Additionally, it is considered relevant for managing and preventing Pneumocystis jirovecii pneumonia (PCP), a condition presenting with severe manifestations often seen in immunocompromised patients. In this context, the medication provides important support in managing this severe infection and supports patients during episodes of heightened discomfort by easing symptoms that create noticeable physiological strain.


Alleviating Acute Gastrointestinal Distress

The drug is relevant in clinical settings marked by heightened gastrointestinal symptoms from specific bacterial infections, including shigellosis and certain severe cases of traveler's diarrhea. It is applied to address symptoms such as watery or bloody diarrhea, abdominal cramping, and infection-related fever. This supportive therapeutic benefit may assist with maintaining functional stability and contribute to easing the overall symptom load associated with diarrheal episodes.

Quick Fact: Relief for Acute Discomfort The medicine is commonly used to help manage symptoms related to systemic imbalance and heightened physiological activity, providing supportive relief that assists with maintaining functional stability.

Regulatory References

  1. NIH StatPearls overview of Trimethoprim Sulfamethoxazole
Advertisements

Eligibility and Restrictions for Use

The eligibility to use Trimzole DS (Co-trimoxazole) is defined by official regulatory documentation, which outlines specific populations for whom the medicine is either permitted, restricted, or strictly contraindicated.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed: Adults, adolescents, and pediatric patients 2 months of age and older are approved for labeled conditions.
Populations for whom use is contraindicated: Patients with known hypersensitivity to its components or sulfonamides. Infants less than 2 months of age. Patients with severe hepatic damage, severe renal insufficiency where monitoring is not possible, or megaloblastic anemia due to folate deficiency.
Eligibility-related restrictions: Use is restricted in patients with non-severe renal impairment or G6PD deficiency, and in the geriatric population due to increased susceptibility to adverse effects.
Pregnancy and lactation status: Use is generally restricted or avoided during the first and late stages of pregnancy and contraindicated during lactation if the infant is under 2 months old.

Eligibility Classifications (High-Level)

Classification Regulatory Status
Age-related prohibition: Infants under 2 months of age are contraindicated by regulatory labels.
Condition-based prohibition: Severe liver or kidney damage and folate deficiency-related anemia are contraindications.

Connection to the overall eligibility profile: Official regulatory documents strictly define who can and cannot use Trimzole DS based on age criteria, absolute prohibitions, and specific disease states. Eligibility is restricted for populations with known sensitivities or impaired organ function, using formal classifications such as "contraindicated" to establish non-eligibility. The use of this medicine is therefore confined to specific population groups where these major regulatory exclusions and conditional monitoring requirements do not apply.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Trimzole DS, a combination of sulfamethoxazole and trimethoprim, has the potential to interact with a variety of other medicines, potentially altering the effects of either Trimzole DS or the co-administered drug. The interaction profile is particularly critical when combining it with medicines used for diabetes and heart disease.

Trimzole DS can increase the blood-thinning effect of Warfarin, which raises the risk of bleeding. For diabetes medications, specifically sulfonylureas (like glipizide or glyburide) and Metformin, Trimzole DS may enhance their blood glucose-lowering effects, leading to a significant risk of hypoglycemia (very low blood sugar). Monitoring of blood glucose is essential during co-administration.

Simultaneous use with certain heart and blood pressure medicines, such as ACE inhibitors or ARBs, is associated with an increased risk of hyperkalemia (high potassium levels in the blood), which can be clinically serious and affect heart rhythm. It can also increase the concentration of medicines like Phenytoin (an anticonvulsant), leading to toxicity.

Do not use this medicine if you have a known allergy to sulfonamides or trimethoprim, or in infants less than six weeks to two months of age. Patients are advised to inform their healthcare provider of all prescription, over-the-counter, and herbal products currently being taken.

Advertisements

Mechanism of Action

How Trimzole DS Works: Pharmacodynamic Mechanism


Dual and Sequential Blockade of Folic Acid Synthesis

Trimzole DS achieves its mechanism of action through the dual-target inhibition of the bacterial folic acid synthesis pathway. The first active ingredient, Sulfamethoxazole, acts as a competitive inhibitor of the bacterial enzyme Dihydropteroate Synthase (DHPS). The second active ingredient, Trimethoprim, then inhibits the subsequent enzyme, Dihydrofolate Reductase (DHFR) . This sequential, two-step interference with a vital metabolic process provides a synergistic mechanism.


Cessation of Bacterial DNA Production

The coordinated inhibition causes a profound depletion of biologically active tetrahydrofolate ( H4 PteGlu). This molecular consequence prevents the bacteria from manufacturing necessary purines and pyrimidines for DNA and RNA synthesis. This key mechanistic cascade causes a complete metabolic shutdown, which leads directly to bactericidal cell death. The resulting bactericidal cell death leads to a systemic reduction in the pathogen load.

Advertisements

Dosage and Administration Information

Trimzole DS (co-trimoxazole) is administered through two officially approved routes: the Oral route, commonly utilizing the Double Strength (DS) tablets or oral suspension, and by Intravenous (IV) Infusion for severe infections or when the oral form is not feasible.

Standard dosing for common bacterial infections, such as acute uncomplicated urinary tract infections or acute exacerbation of chronic bronchitis, involves the administration of one DS tablet (800 mg SMX/ 160 mg TMP) on a twice-daily (every 12 hours) frequency. However, treatment of severe conditions like Pneumocystis jirovecii Pneumonia (PJP) requires a higher daily dosage, which is calculated based on the patient’s body weight and delivered in divided doses up to every six hours.

The total treatment duration is determined by the specific infection being addressed. Courses are short, typically 5 days, for conditions like shigellosis, while others, such as UTIs, usually require 10 to 14 days. Treatment for PJP is significantly longer, lasting 14 to 21 days, or may be used in an intermittent, long-term pattern for prophylaxis.

Usage instructions state that oral forms are generally taken with food or drink to enhance tolerability, and patients are directed to maintain high fluid intake throughout the course of therapy. For IV administration, the concentrated solution must be appropriately diluted prior to infusion and delivered slowly over a period of 60 to 90 minutes. Dosage adjustments are officially required for patients with impaired renal function, specifically those with a Creatinine Clearance between 15 and 30 mL/min.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trimzole DS

This summary describes the types of research and outcomes that have been investigated for Trimzole DS (Co-trimoxazole), focusing only on the available evidence and what remains uncertain, without making any recommendations or claims about what the medicine will do for an individual.


Evidence for Use in Urinary Tract and Respiratory Infections

Research into the use of this medicine for common bacterial conditions, such as uncomplicated urinary tract infections (UTIs) and acute episodes of chronic bronchitis, was evaluated in short-term Randomized Controlled Trials (RCTs) and various comparative studies. For UTIs, studies monitored outcomes related to physical discomfort and documented rates of microbial clearance after short courses of therapy. Continuous monitoring of local pathogen resistance is needed to contextualize this older evidence.

Evidence for Prevention and Treatment of Specific Opportunistic Infections

Research has focused significantly on the use of this medicine for preventing and treating Pneumocystis jirovecii Pneumonia (PCP), a serious opportunistic infection, particularly in immunocompromised individuals. For the treatment of PCP, Comparative Studies have monitored severe outcomes such as all-cause mortality and composite treatment failure. For prophylaxis (prevention), long-term Observational Studies track the incidence of new PCP events over observation periods that can last for years.


Evidence in Special Populations and Long-Term Data

Research has specifically monitored outcomes for this medicine in children aged two months and older. Studies for infants under two months of age are not available due to specific safety concerns documented in the research record. In older adult populations, findings indicate that co-prescribing this medicine with certain common blood pressure medications was associated with an increased risk of severe changes in blood potassium levels in some observational studies. Most evidence, particularly for common acute infections, is derived from short-term trials. Long-term patterns of infection recurrence following cessation of prophylaxis are not fully established.

Key Studies & References

  1. Trimethoprim Sulfamethoxazole - StatPearls - NCBI Bookshelf
  2. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens (Study on resistance)
  3. Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis
  4. Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Trimzole DS (FAQ)

Q: What is the difference between Trimzole DS and regular Trimzole?

Trimzole DS (Double Strength) contains a higher concentration of the active ingredients (sulfamethoxazole and trimethoprim) compared to the regular strength formulation. The DS dosage form typically contains a Double Strength amount of active ingredients, while the regular strength contains half that concentration.

Q: Can Trimzole DS be used for conditions other than the main one listed?

Regulatory indications show the drug is approved to treat various bacterial infections beyond common urinary tract infections. These include acute infective exacerbation of chronic bronchitis, certain ear infections (otitis media), Shigellosis, traveler's diarrhea, and Pneumocystis jirovecii Pneumonia (PJP).

Q: Does Trimzole DS cause drowsiness?

Official regulatory labels list drowsiness and dizziness as nervous system side effects that have been reported with this medication. Patients are informed that they should assess how the medicine affects them before engaging in activities like driving or operating machinery.

Q: Is Trimzole DS known to affect fertility?

Regulatory information primarily addresses risks during pregnancy. The official drug labels do not explicitly describe long-term effects on fertility (the ability to conceive in either sex). Official regulatory information notes risks during the first trimester of pregnancy and restricts use in late stages, which requires careful planning for women of childbearing age.

Q: Does Trimzole DS have any known interactions with alcohol?

Moderate interaction warnings exist in regulatory documents for the combination of the sulfamethoxazole component and alcohol (ethanol). Official documents recommend that patients discuss alcohol consumption with a doctor, as some individuals may experience unpleasant side effects like fast heartbeats, flushing, or nausea.

Q: Why is the DS (Double Strength) version available?

The Double Strength tablet is an available dosage form intended for patient convenience. Official product information states it is designed to deliver a higher quantity of the active ingredients (sulfamethoxazole and trimethoprim) at the standard dosing interval.

Q: Is there any research about Trimzole DS being used for [Related but non-approved condition]?

While official drug approval is confined to specific labeled uses, regulatory and medical literature notes that research has been conducted regarding non-approved conditions, such as acne, Listeria, and MRSA infections. Studies concerning non-approved uses do not constitute official endorsement or approval by regulatory bodies.

Q: Is Trimzole DS a non-prescription drug?

According to regulatory classification, Trimzole DS (co-trimoxazole) is a prescription-only medication. It is an antibiotic that requires a healthcare provider's authorization for dispensing.

Q: Can Trimzole DS affect sleep patterns?

Adverse events reported in the regulatory profile include both difficulty with sleeping ('trouble sleeping') and lethargy (unusual tiredness). This indicates that an effect on sleep patterns is described as possible in official documentation.

Q: What does 'contraindicated' mean in relation to Trimzole DS?

A drug is "contraindicated" when the official regulatory label states that it should not be used in a particular situation because the risk of harm clearly outweighs any potential benefit. Examples of contraindications for this medicine include severe liver or kidney disease and known hypersensitivity to its components.

Q: Is there a generic version of Trimzole DS available?

Yes, the active ingredients in this drug are available in generic versions. These versions are typically labeled under the generic names sulfamethoxazole and trimethoprim, or co-trimoxazole.

Q: Are there different brand names for the same active ingredient as Trimzole DS?

Yes, the combination of active ingredients (sulfamethoxazole and trimethoprim) is marketed under various brand names, including Bactrim and Septra DS, depending on the region and manufacturer.

Q: Can Trimzole DS be split or crushed?

The tablets may be crushed and mixed in a small amount of water or soft food if swallowing whole is difficult. However, official information recommends that confirmation of the correct method be obtained from a pharmacist or doctor regarding the specific formulation.

Q: What research is currently being done on Trimzole DS?

Public clinical trial registries show that research on this medication is currently being conducted. These ongoing studies include investigations into its use for conditions like tuberculosis, spontaneous bacterial peritonitis in cirrhosis, and certain infections in children with tumors.

Q: Is it safe to drive after taking Trimzole DS?

The drug may cause nervous system side effects such as dizziness, confusion, or drowsiness. Regulatory literature indicates that a patient should avoid driving or operating machinery if nervous system symptoms like dizziness, confusion, or drowsiness occur.

Q: Is the active ingredient in Trimzole DS a controlled substance?

No, the active ingredients (sulfamethoxazole and trimethoprim) are classified as antibiotics. They are not listed or regulated as controlled substances by the Drug Enforcement Administration (DEA).

Q: Is it common for people to experience joint pain while on Trimzole DS?

Joint or muscle pain (arthralgia/myalgia) is listed among the possible side effects in the drug's regulatory profile. However, this reaction is not typically classified in the 'Very Common' or 'Common' frequency categories found in official documents.

Q: Does Trimzole DS contain common allergens like gluten or lactose?

Official excipient lists for some formulations of the tablets show that they contain lactose as a non-active ingredient. For specific allergens, such as gluten, the exact product labeling provided by the manufacturer is the required reference point.

Q: Is Trimzole DS known to cause weight gain or loss?

According to the official regulatory safety profile, weight loss is listed as an adverse event of unknown frequency. Weight gain is not commonly listed as a direct side effect of this medication.

Q: Can Trimzole DS interact with over-the-counter pain relievers?

Regulatory documents state that this drug has the potential to interact with certain medications that affect the blood, kidney function, or potassium levels. Official information suggests that certain non-steroidal anti-inflammatory drugs (NSAIDs) should be used with caution during therapy. Official documents stress the importance of disclosing all over-the-counter pain relievers to a healthcare provider.

Q: Can I take Trimzole DS if I'm already taking a supplement?

Official product information notes that the trimethoprim component of this medicine may affect the body's folic acid levels. While folic acid supplementation may be given if necessary, it is recommended that patients inform their doctor of all supplements, including vitamins and minerals, they are currently taking.

Q: Does Trimzole DS interact with herbal remedies like St. John's Wort?

According to regulatory sources, the herbal remedy St. John's wort (Hypericum perforatum) may reduce the blood concentration of the trimethoprim component of the medicine. This action could potentially make the medication less effective, and its use requires discussion with a healthcare provider.

Q: What are the known severe allergic reaction signs to Trimzole DS?

Signs that may precede severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS), are described in regulatory documents. These signs can include high fever, severe headache, painful mouth sores, inflamed eyes (conjunctivitis), or redness and blistering of the skin. The presence of these symptoms is officially noted as a reason to seek immediate medical review.

Q: Does taking Trimzole DS require regular blood tests?

Complete blood counts are typically obtained regularly, according to official guidelines, especially during prolonged therapy lasting more than 14 days, due to a documented risk of blood disorders. Additionally, the co-administration with certain diabetes medications requires close blood glucose monitoring.

Q: How does the DS formulation change the drug's activity?

The "DS" (Double Strength) formulation contains twice the amount of the active ingredients compared to the standard tablet. Regulatory studies have shown the DS tablet to be bioequivalent, meaning it delivers the same amount of drug to the bloodstream. This formulation is often available for patient convenience and reduced pill burden.

Q: Does Trimzole DS interact with common cold or flu medications?

Official information contains general warnings about interactions with over-the-counter products that may affect kidney function, potassium, or blood-thinning. Since many cold and flu medications fall into these categories, regulatory bodies emphasize the need for a healthcare provider to review all such products before use.

Q: Does Trimzole DS affect blood pressure or heart rate?

The drug is associated with changes in electrolyte levels, specifically high or low potassium (hyperkalemia/hypokalemia), which can lead to a fast or irregular heartbeat. Regulatory reports also note that hypotension (low blood pressure) has been described in rare cases.

Advertisements

How should Trimzole DS be stored and disposed of?

Storage and Handling

Trimzole DS (sulfamethoxazole and trimethoprim) should be stored at room temperature, typically between 68 F and 77 F (20 C and 25 C). Keep the medication in the container it came in, tightly closed, and store it away from excess heat and moisture (do not store it in the bathroom). For the oral liquid form, protection from light is also required. Keep all forms of this medication out of the reach and sight of children at all times.

Disposal Instructions

To dispose of unused or expired Trimzole DS, the best option is to use a drug take-back program. You should not flush this medication down the toilet. If a take-back program is unavailable and the medicine is not on the official FDA flush list, you may dispose of it in the household trash. To do this, remove the drug from its original container, mix it with an undesirable substance (such as used coffee grounds or kitty litter), and place the mixture in a sealed bag or container before discarding it in the trash. This prevents accidental ingestion by people or pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Trimzole DS found in:

A-Z Index: